PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA

The U.S. Food and Drug Administration recently approved two poly‐adenosine diphosphate‐ribose polymerase (PARP) inhibitors, olaparib and rucaparib, for treatment of biomarker‐positive metastatic castrate resistant prostate cancer. The benefits of PARP inhibition have been well characterized in patie...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Oncologist
Main Authors: Risdon, Emily N., Chau, Cindy H., Price, Douglas K., Sartor, Oliver, Figg, William D.
Format: Artigo
Sprog:Inglês
Udgivet: John Wiley & Sons, Inc. 2020
Fag:
Genitourinary Cancer
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7794174/
https://ncbi.nlm.nih.gov/pubmed/32790034
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0697
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker